ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
31 announcements
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
Epigral Ltd will invest ₹650 Crore to add 1,25,000 TPA of Epoxy Resin & Formulations capacity at its Dahej facility, expected by H2 FY2028.
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
Epigral reported Q1FY27 PAT of ₹99 Crore, a 25% YoY increase. The company plans ₹600 Crore capex for Epoxy Resin and Multi-Purpose Plant.
Epigral Limited plans to establish a new manufacturing facility for Epoxy Resin and Multi-Purpose Plant at Dahej, Gujarat. The project requires an investment of ₹600 Crore.
Epigral Ltd reported revenue from operations of ₹705.4 Cr (+16.3% YoY) and net profit of ₹99.7 Cr (-38.0% YoY) for Q1 FY27.
Epigral Ltd scheduled a board meeting for July 27, 2026. The board will consider the company's first quarter unaudited financial results.
Epigral Limited clarified that recent volume and price movements are due to market conditions. The company confirms no undisclosed price-sensitive information exists.
Epigral Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026. The report details the distribution of shareholdings among various investor categories.
CRISIL reaffirmed Epigral Limited's long-term rating at AA/Stable and short-term rating at A1+. The ratings cover bank loan facilities worth Rs. 1050 Crore.
Epigral Limited incorporated a wholly-owned subsidiary, Epigral Advanced Materials Limited, for chemical manufacturing. The subsidiary has a paid-up capital of Rs. 1 lakh.
Epigral Limited concluded its 19th AGM on June 08, 2026. Shareholders approved six resolutions, including adoption of financial statements and declaration of a ₹5.00 final dividend.
CRISIL reaffirmed Epigral Limited's long-term rating at AA/Stable and short-term rating at A1+. The assessment covers bank loan facilities totaling ₹1050 Crore.
Epigral Limited announced the successful passage of special resolutions via postal ballot for director re-appointments. Members approved all items with requisite majority through remote e-voting.
Epigral Limited set June 01, 2026, as the record date for final dividend payment. The dividend remains subject to shareholder approval at the upcoming AGM.
Epigral achieved highest-ever quarterly revenue of ₹736cr in Q4FY26 with 23% EBITDA margins, driven by 15% volume growth and improved plant utilization.
Epigral achieved record Q4 revenue driven by 15% volume growth, though full-year profits were dragged by earlier operational headwinds and suppressed pricing.
Epigral delivered record quarterly revenue of ₹736cr, driven by a 15% QoQ volume surge and plant stabilization after major maintenance, despite geopolitical volatility.
Epigral Limited's Board has recommended a final dividend of ₹5 per equity share for the financial year 2025-2026. The record date and book closure details will be announced later. This distribution reflects the company's commitment to sharing profits with shareholders following its board meeting on May 2, 2026.
Epigral Ltd reported record Q4FY26 revenue of ₹736 Crore, up 17% year-on-year, driven by volume growth and improved realizations. The Board proposed a final dividend of ₹5 per share. While PAT stood at ₹82 Crore, EBITDA margins improved to 23%. The company continues its strategic capex expansions in CPVC and Epichlorohydrin capacities.
Epigral Limited delivered record Q4FY26 revenue of ₹736 Cr (up 22% QoQ) with EBITDA margins improving to 23%. Strategy focuses on transitioning towards a 70% high-margin Derivatives & Specialty revenue mix by FY28.
Epigral reported record Q4FY26 revenue of ₹736 Cr (up 22% QoQ) with 23% EBITDA margins. Growth driven by volume recovery and higher contribution (54%) from derivatives and specialty chemicals.
Epigral Ltd reported revenue from operations of ₹736.2 Cr (+17.3% YoY) and net profit of ₹81 Cr (-6.8% YoY) for Q4 FY26.
Epigral Limited reported its FY2025-26 audited financial results. The company recommended a final dividend of Rs. 5.00 (50%) per equity share of face value Rs. 10. The standalone annual revenue stood at ₹2,527.18 Crore with a profit after tax of ₹333.01 Crore.
Epigral Limited has scheduled a Board Meeting for May 2, 2026, to approve audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also consider a final dividend recommendation. The trading window remains closed until May 4, 2026.
Epigral Ltd has scheduled a Board Meeting for May 2, 2026. The directors will consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Additionally, the board will consider recommending a final dividend for the financial year.
Epigral Limited has issued a Postal Ballot notice to shareholders for the re-appointment of Mr. Sanjay Asher, Mr. Kanubhai Patel, and Mr. Raju Swamy as Independent Directors. Each re-appointment is for a second five-year term starting May 20, 2026. Voting concludes on May 19, 2026.
Epigral Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of three Non-Executive Independent Directors: Mr. Sanjay Asher, Mr. Kanubhai Patel, and Mr. Raju Swamy. Each re-appointment is for a second five-year term starting May 20, 2026. E-voting remains open from April 20 to May 19, 2026.
Epigral Ltd has approved the re-appointment of Mr. Sanjay Asher, Mr. Kanubhai Patel, and Mr. Raju Swamy as Non-Executive Independent Directors for a second five-year term effective May 20, 2026. These appointments remain subject to shareholder approval via postal ballot. The move ensures leadership continuity for the company's board through 2031.
Epigral Ltd reported net profit of ₹39.1 Cr (-62.4% YoY) for Q3 FY26.